Key Takeaways
- Domestic formulation engine outperformed: Domestic business grew ~12% in Q3, beating the 8.9% IPM growth rate, with the pain segment (over 50% of the business) driving at 13%.
- Export formulations surged on West Africa: Export formulations grew ~17%, led by French-speaking African markets which jumped ~69% in Q3 and ~41% for the nine-month period.
- Margins expanded on mix shift: Stand-alone EBITDA margin improved ~181 bps to 26.09% and consolidated improved ~228 bps to 22.5%, driven by a product mix shift toward higher-margin branded and chronic businesses and a decline in lower-margin institutional sales.
- Unichem remains the drag, with a timeline: Unichem's U.S. market share loss from 2-3 major molecules will pressure margins for 1-2 more quarters, with recovery expected thereafter at lower prices, supported by new Ipca-originated launches.
- What to watch next quarter: Whether the sharp U.K. pricing recovery sustains, the pace of Unichem's U.S. market share stabilization, and any update on the biosimilar program's manufacturing start.
Domestic Formulation: The Core Growth Engine
- Broad-based outperformance: Domestic business grew ~12% versus IPM growth of 8.9%, with both chronic and acute segments contributing. The pain segment, which accounts for over half of domestic revenue, grew 13%.
- Chronic rebound: Cardiovascular grew 16% after an earlier restructuring period, and diabetes grew 14%. CNS grew 19%, derma grew 22%, and neurology grew 17%, compensating for a ~21% decline in the antimalarial segment.
- Growth expectation: Management expects to continue beating the market, with domestic business growth pegged at ~10% to 12% over a longer period.
Unichem: The Margin Recovery Story
- The problem: Unichem lost high-volume U.S. business on 2-3 major molecules due to increased competition and price reductions. The decline started in Q2 and will continue for 1-2 more quarters. The basic business, excluding the Ipca portfolio, grew only ~2%.
- The recovery path: Management expects to recover lost market share on existing molecules, albeit at lower prices, while launching 4-5 more Ipca-originated molecules in the U.S. market. Five Ipca molecules already launched have reached over 25% market share after 1-1.5 years, benefiting from backward integration.
- Margin timeline: Unichem EBITDA margins currently sit near ~8%. Management aims to reach ~15% in 2-3 years, with gradual improvement toward ~20% as European filings and registrations materialize. The manufacturing plant has significant capacity; margins will automatically improve once utilized.
- Stand-alone growth: Once U.S. market share loss is regained, Unichem's stand-alone portfolio is expected to grow 7-8% annually, with overall top-line growth of 8-10%.
Harish Kamath: "In the existing molecule also, we will recover our market share, whatever we have lost, albeit at a lower price. Plus new products also, they continue to launch in the marketplace."
Export Formulations: West Africa Leads
- Regional breakout: Export formulations grew ~17% in Q3, with French-speaking West African markets growing ~69% in the quarter and ~41% over nine months.
- U.K. pricing whiplash: The U.K. market experienced what management called a "blood bath on pricing," with many products sold at losses due to fierce competition. In the last month, a sharp recovery of 30-40% in prices was observed, attributed to inventory clearance of short-expiry materials. Management now hopes to do better business there.
- European stability: The European business outside the U.K., including Spain and smaller Scandinavian countries, is described as very steady with good margins. The company has no presence in Germany, France, or Italy.
- Growth expectation: Promotional branded international business, the highest-margin segment, is expected to grow ~10-12% over the longer period.
Ajit Kumar Jain: "That business was fiercely competitive. And practically, in that market, there was a blood bath on pricing vertically. A lot of products we're selling at losses in that market."
Margin Architecture: Mix Shift at Work
- The driver: Stand-alone EBITDA margin improved ~181 bps to 26.09%, and consolidated improved ~228 bps to 22.5%. The expansion came from a product mix shift: businesses with better margins are growing faster, while lower-margin institutional business declined. Material cost-to-sales ratio fell to ~24%, with a full-year improvement of ~3.3-3.4% expected.
- The margin hierarchy: Promotional branded international sits at the top, followed by domestic branded, then generic (ex-U.K.), institutional, U.K. business, and API business at the bottom. The domestic chronic segment is growing faster than the acute antimalarial segment, lifting the overall mix.
- Forward expectation: Management expects EBITDA margin improvement of 150 bps or more per year if top-line growth stays at ~10-12%, with a potential 300 bps improvement over the next two years. Detailed guidance will be provided after the budget exercise completes by March.
- API flatness: The API business was flat at ~INR317 crore in Q3, partly due to lower domestic antimalarial business and a decline in Shirasho peptides manufactured at the CRAMS facility. API growth is expected to run slightly below the 10-12% company average.
U.S. Business: Ipca Portfolio Builds, Unichem Resets
- Ipca's own U.S. growth: Q3 U.S. business grew ~17%, largely driven by the Ipca portfolio of own products and the Bayshore portfolio of third-party trading products routed through Unichem. Five Ipca molecules currently marketed have reached over 25% market share, benefiting from backward integration.
- Launch pipeline: Another 4-5 molecules are to be launched in the next 6-12 months, with 5-7 molecules expected to be commercialized over the next 12-15 months. The company files ~5-6 products every year and adds a similar number annually.
- Approval uncertainty: Over 30 filings are pending, with ~8-10 approvals still awaited. Management said it is difficult to give a commercialization timeline as it depends on the approval cycle.
- Unichem's U.S. reset: The market share loss on 2-3 major molecules will take 1-2 more quarters to stabilize. Recovery will come from regaining share at lower prices plus new Ipca-originated launches.
Harish Kamath: "whatever five products I am today marketing, it is almost now 2 years and now we have reached a market share. Most of the molecule is 25% plus because they are all our backward-integrated molecules."
Biosimilars & Other Initiatives
- Biosimilar program: The company now has five biosimilar candidates. Technology transfer has started for two products, and manufacturing is expected to start shortly. The company has taken regulatory opinions on protocols from UK MHRA, European authorities, and the US FDA, and is targeting all global markets.
- GLP-1 opportunity: Management is working on in-licensing opportunities for GLP-1 products and is also considering in-house manufacturing.
- Solar project: Unichem has a solar project underway for green energy with a capital outlay of ~INR50 crore.
- R&D output: R&D output has increased, with filings building up across all markets and ROW filings moving up, expected to have a better impact on generic businesses going forward.
Ajit Kumar Jain: "We have already taken opinion on our regulatory framework from U.K. MHRA. We have taken from European authorities and also from U.S. FDA. So all the three agencies, we have taken that opinion on protocols and everything. So everything is going on in that line."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unichem U.S. market share loss | Decline to continue before recovery begins | 1-2 more quarters |
| Unichem EBITDA margin target | Reach ~15% | 2-3 years |
| Unichem EBITDA margin target | Gradually improve to ~20% | As European filings/registrations come in |
| Unichem stand-alone portfolio growth | 7-8% annually | Once market share loss regained |
| Ipca U.S. product launches | 4-5 more molecules launched | Next 6-12 months |
| Ipca U.S. commercialization | 5-7 molecules commercialized | Next 12-15 months |
| Ipca U.S. annual filings | ~5-6 filings every year | Ongoing |
| Domestic business growth | ~10-12% | Longer period |
| Overall company growth | ~10-11% | Longer period |
| EBITDA margin improvement | 150 bps+ per year; 300 bps potential | Next 2 years, if 10-11% growth holds |
| Full-year material cost improvement | ~3.3-3.4% reduction in material cost-to-sales ratio | FY26 |
| Detailed business and margin guidance | To be provided | After budget exercise completes by March |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹2,245 cr, growth of ~6.5% YoY from ₹2,393 cr |
| Consolidated revenue (9M FY26) | ₹7,258 cr, growth of ~8.44% YoY from ₹6,993 cr |
| Stand-alone EBITDA margin | 26.09%, improved ~1.81 ppt YoY from 24.25% |
| Consolidated EBITDA margin | ~22.5%, improved ~2.28 ppt YoY from 19.87% |
| Consolidated EBITDA margin (9M FY26) | 20.79%, improved ~1.61 ppt YoY from 19.18% |
| Stand-alone material cost-to-sales ratio | ~24%, improved ~3.64 ppt YoY |
| Stand-alone material cost-to-sales ratio (9M FY26) | 25.37%, improved ~3.36 ppt YoY from 28.73% |
| Domestic formulation growth | ~12% YoY |
| Export formulation growth | ~17% YoY |
| API business revenue | ~₹317 cr, flat YoY |
| API business growth (9M FY26) | ~14% YoY to ~₹1,051 cr from ₹924 cr |
| Unichem EBITDA margin | ~8% |
| Unichem overall revenue growth target | 8% to 10% over next 2 to 3 years |
| Unichem EBITDA margin target | ~15% in 2 to 3 years, gradually improving to ~20% |
| Ipca U.S. business (Ipca + Unichem consolidated) | ~₹395 cr, growth of ~17% YoY from ~₹339 cr |
| Ipca-manufactured U.S. portfolio (5 products, 9M FY26) | ~₹1 cr to ₹1.1 cr |
| Ipca U.S. filings in current year | 4 filings, annual run-rate of ~5 to 6 filings |
| Promotional branded business growth outlook | ~10% to 12% over longer period |
| Overall company growth outlook | ~10% to 11% |
| EBITDA margin improvement outlook | 1.5%+ per year if top line growth is ~10% to 12% |